| Date: 7 th October, 2022 |
|--|
| Your Name: Zsofia Szarvas |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in reducing symptoms of post |
| COVID syndrome |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initia | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X_None | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | XNone | | | |
|------|--|---------------------------------|------------|--|--|
| | lectures, presentations, speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| | educational events | | | | |
| 6 | Payment for expert | XNone | | | |
| | testimony | | | | |
| _ | Command for adding | V. Nama | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | XNone | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data | XNone | | | |
| | Safety Monitoring Board or | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role | XNone | | | |
| | in other board, society, committee or advocacy | | | | |
| | group, paid or unpaid | | | | |
| 11 | Stock or stock options | XNone | | | |
| | | | | | |
| | | | | | |
| 12 | Receipt of equipment, | X_None | | | |
| | materials, drugs, medical | | | | |
| | writing, gifts or other services | | | | |
| 42 | | V N | | | |
| 13 | Other financial or non- financial interests | XNone | | | |
| | inialiciai inicerests | | | | |
| | | | | | |
| | | | | | |
| Plea | se summarize the above co | nflict of interest in the follo | owing box: | | |
| | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |

| Date: 7 th October, 2022 |
|---|
| Your Name: Monika Fekete |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in reducing symptoms of post- |
| COVID syndrome |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | Yes | |
| 3 | Royalties or licenses | X_None | |
| 4 | Consulting fees | X None | |

| 6 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | XNone | |
|----|--|--------|--|
| 7 | Support for attending meetings and/or travel | XNone | |
| 8 | Patents planned, issued or pending | XNone | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | XNone | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone | |
| 11 | Stock or stock options | XNone | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | X_None | |
| 13 | Other financial or non- financial interests | XNone | |

Please summarize the above conflict of interest in the following box:

Monika Fekete was supported by project no. TKP2021-NKTA-47 has been implemented with the support provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the TKP2021-NKTA funding scheme. The funding source had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Please place an "X" next to the following statement to indicate your agreement:

| Date: 7 th October, 2022 |
|---|
| Your Name: Rita Horvath |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in reducing symptoms of pos |
| COVID syndrome |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | XNone | | | |
|------|--|---------------------------------|------------|--|--|
| | lectures, presentations, speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| | educational events | | | | |
| 6 | Payment for expert | XNone | | | |
| | testimony | | | | |
| _ | Command for adding | V. Nama | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | XNone | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data | XNone | | | |
| | Safety Monitoring Board or | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role | XNone | | | |
| | in other board, society, committee or advocacy | | | | |
| | group, paid or unpaid | | | | |
| 11 | Stock or stock options | XNone | | | |
| | | | | | |
| | | | | | |
| 12 | Receipt of equipment, | X_None | | | |
| | materials, drugs, medical | | | | |
| | writing, gifts or other services | | | | |
| 42 | | V N | | | |
| 13 | Other financial or non- financial interests | XNone | | | |
| | inialiciai inicerests | | | | |
| | | | | | |
| | | | | | |
| Plea | se summarize the above co | nflict of interest in the follo | owing box: | | |
| | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |

| ate: 7 th October, 2022 |
|---|
| our Name: Maya Shimizu |
| lanuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in reducing symptoms of pos |
| OVID syndrome |
| lanuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | XNone | | | | |
|------|---|---------|--|--|--|--|
| | lectures, presentations, speakers bureaus, | | | | | |
| | manuscript writing or | | | | | |
| | educational events | | | | | |
| 6 | Payment for expert | XNone | | | | |
| | testimony | | | | | |
| _ | Command for adding | V. Nama | | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 8 | Patents planned, issued or | XNone | | | | |
| | pending | | | | | |
| | | | | | | |
| 9 | Participation on a Data Safety Monitoring Board or | XNone | | | | |
| | | | | | | |
| | Advisory Board | | | | | |
| 10 | Leadership or fiduciary role | XNone | | | | |
| | in other board, society, committee or advocacy | | | | | |
| | group, paid or unpaid | | | | | |
| 11 | Stock or stock options | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 12 | Receipt of equipment, | X_None | | | | |
| | materials, drugs, medical | | | | | |
| | writing, gifts or other services | | | | | |
| 42 | | V N | | | | |
| 13 | Other financial or non- financial interests | XNone | | | | |
| | inialiciai inicerests | | | | | |
| | | | | | | |
| | | | | | | |
| Plea | Please summarize the above conflict of interest in the following box: | | | | | |
| | | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |

| Date: 7 th October, 2022 |
|---|
| Your Name: Fuko Tsuhiya |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in reducing symptoms of post- |
| COVID syndrome |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initia | l planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X_None | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | XNone | | | | |
|------|---|---------|--|--|--|--|
| | lectures, presentations, speakers bureaus, | | | | | |
| | manuscript writing or | | | | | |
| | educational events | | | | | |
| 6 | Payment for expert | XNone | | | | |
| | testimony | | | | | |
| _ | Command for adding | V. Nama | | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 8 | Patents planned, issued or | XNone | | | | |
| | pending | | | | | |
| | | | | | | |
| 9 | Participation on a Data Safety Monitoring Board or | XNone | | | | |
| | | | | | | |
| | Advisory Board | | | | | |
| 10 | Leadership or fiduciary role | XNone | | | | |
| | in other board, society, committee or advocacy | | | | | |
| | group, paid or unpaid | | | | | |
| 11 | Stock or stock options | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 12 | Receipt of equipment, | X_None | | | | |
| | materials, drugs, medical | | | | | |
| | writing, gifts or other services | | | | | |
| 42 | | V N | | | | |
| 13 | Other financial or non- financial interests | XNone | | | | |
| | inialiciai inicerests | | | | | |
| | | | | | | |
| | | | | | | |
| Plea | Please summarize the above conflict of interest in the following box: | | | | | |
| | | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |

| Date: 7 th October, 2022 |
|---|
| Your Name: Ha Eun Choi |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in reducing symptoms of post- |
| COVID syndrome |
| Manuscript number (if known): |
| |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initia | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | XNone | | | | |
|------|---|---------|--|--|--|--|
| | lectures, presentations, speakers bureaus, | | | | | |
| | manuscript writing or | | | | | |
| | educational events | | | | | |
| 6 | Payment for expert | XNone | | | | |
| | testimony | | | | | |
| _ | Command for adding | V. Nama | | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 8 | Patents planned, issued or | XNone | | | | |
| | pending | | | | | |
| | | | | | | |
| 9 | Participation on a Data Safety Monitoring Board or | XNone | | | | |
| | | | | | | |
| | Advisory Board | | | | | |
| 10 | Leadership or fiduciary role | XNone | | | | |
| | in other board, society, committee or advocacy | | | | | |
| | group, paid or unpaid | | | | | |
| 11 | Stock or stock options | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 12 | Receipt of equipment, | X_None | | | | |
| | materials, drugs, medical | | | | | |
| | writing, gifts or other services | | | | | |
| 42 | | V N | | | | |
| 13 | Other financial or non- financial interests | XNone | | | | |
| | inialiciai inicerests | | | | | |
| | | | | | | |
| | | | | | | |
| Plea | Please summarize the above conflict of interest in the following box: | | | | | |
| | | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |

| Date: 7 th October, 2022 |
|---|
| Your Name: Katica Kúp |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in reducing symptoms of pos |
| COVID syndrome |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | X_None | | | |
|------|---|---------|--|--|--|
| | lectures, presentations, speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| | educational events | | | | |
| 6 | Payment for expert | XNone | | | |
| | testimony | | | | |
| _ | Command for adding | V. Nama | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | XNone | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data | XNone | | | |
| | Safety Monitoring Board or | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role | XNone | | | |
| | in other board, society, committee or advocacy | | | | |
| | group, paid or unpaid | | | | |
| 11 | Stock or stock options | XNone | | | |
| | | | | | |
| | | | | | |
| 12 | Receipt of equipment, | X_None | | | |
| | materials, drugs, medical | | | | |
| | writing, gifts or other services | | | | |
| 42 | | V N | | | |
| 13 | Other financial or non- financial interests | XNone | | | |
| | inialiciai inicerests | | | | |
| | | | | | |
| | | | | | |
| Plea | Please summarize the above conflict of interest in the following box: | | | | |
| | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |

| Date: 7 th October, 2022 | |
|--|--------------------------|
| Your Name: Vince Fazekas-Pongor | |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in r | educing symptoms of post |
| COVID syndrome | |
| Manuscript number (if known): | |
| In the interest of transparency, we ask you to disclose all relationships/activities/interests related to the content of your manuscript. "Related" means any relation with for-profit or parties whose interests may be affected by the content of the manuscript. Disclosure repre | not-for-profit third |

relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | Time frame: past Yes | 36 months |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | XNone | |
|----|--|--------|--|
| 6 | Payment for expert testimony | XNone | |
| 7 | Support for attending meetings and/or travel | XNone | |
| 8 | Patents planned, issued or pending | XNone | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | XNone | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone | |
| 11 | Stock or stock options | XNone | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | X_None | |
| 13 | Other financial or non- financial interests | XNone | |

VFP was supported by project no. TKP2021-NKTA-47, implemented with the support provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the TKP2021-NKTA funding scheme and a project thro

ugh the National Cardiovascular Laboratory Program (RRF-2.3.1-21-2022-00003) provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund and the European University for Well-Being (EUniWell) program (grant agreement number: 101004093/ EUniWell/EAC-A02-2019 / EAC-A02-2019-1). The study was supported by Hungarian Academy of Science Post-COVID grant (number: PC2022-3/2022). The funding sources had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

| Date: / "October, 2022 |
|--|
| Your Name: Kinga Nedda Pete |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in reducing symptoms of post |
| COVID syndrome |
| Manuscript number (if known): |
| |
| |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, | XNone | |
| | provision of study materials, medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | XNone | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | XNone | |
| | | | |
| | | | |

| 4 | Consulting fees | XNone | | | |
|------|---|--------|--|--|--|
| | | | | | |
| 5 | Payment or honoraria for | X None | | | |
| | lectures, presentations, | | | | |
| | speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| 6 | educational events Payment for expert | X None | | | |
| | testimony | XNone | | | |
| | , | | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | XNone | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data | XNone | | | |
| | Safety Monitoring Board or Advisory Board | | | | |
| 10 | Leadership or fiduciary role | X None | | | |
| | in other board, society, | | | | |
| | committee or advocacy group, paid or unpaid | | | | |
| 11 | Stock or stock options | XNone | | | |
| | | | | | |
| | | | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X_None | | | |
| | writing, gifts or other | | | | |
| | services | | | | |
| 13 | Other financial or non- | XNone | | | |
| | financial interests | | | | |
| | | | | | |
| Plea | Please summarize the above conflict of interest in the following box: | | | | |
| | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |

| Date: 7 th October, 2022 |
|--|
| Your Name: Renata Cserjesi |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in reducing symptoms of post |
| COVID syndrome |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initia | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X_None | |
| 4 | Consulting fees | XNone | |

| 5 | • | X_None | | | | |
|---|--|---------|--|--|--|--|
| | lectures, presentations, speakers bureaus, | | | | | |
| | manuscript writing or | | | | | |
| | educational events | | | | | |
| 6 | Payment for expert | XNone | | | | |
| | testimony | | | | | |
| _ | Command for adding | V. Nama | | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 8 | Patents planned, issued or | XNone | | | | |
| | pending | | | | | |
| | | | | | | |
| 9 | Participation on a Data | XNone | | | | |
| | Safety Monitoring Board or | | | | | |
| | Advisory Board | | | | | |
| 10 | Leadership or fiduciary role | XNone | | | | |
| | in other board, society, committee or advocacy | | | | | |
| | group, paid or unpaid | | | | | |
| 11 | Stock or stock options | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 12 | Receipt of equipment, | X_None | | | | |
| | materials, drugs, medical | | | | | |
| | writing, gifts or other services | | | | | |
| 42 | | V N | | | | |
| 13 | Other financial or non- financial interests | XNone | | | | |
| | inialiciai inicerests | | | | | |
| | | | | | | |
| | | | | | | |
| Please summarize the above conflict of interest in the following box: | | | | | | |
| | | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |

| Date: 7 th October, 2022 |
|--|
| Your Name: Regina Bakos |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in reducing symptoms of post |
| COVID syndrome |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initia | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X_None | |
| 4 | Consulting fees | XNone | |

| 5 | • | X_None | | | | |
|---|--|---------|--|--|--|--|
| | lectures, presentations, speakers bureaus, | | | | | |
| | manuscript writing or | | | | | |
| | educational events | | | | | |
| 6 | Payment for expert | XNone | | | | |
| | testimony | | | | | |
| _ | Command for adding | V. Nama | | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 8 | Patents planned, issued or | XNone | | | | |
| | pending | | | | | |
| | | | | | | |
| 9 | Participation on a Data | XNone | | | | |
| | Safety Monitoring Board or | | | | | |
| | Advisory Board | | | | | |
| 10 | Leadership or fiduciary role | XNone | | | | |
| | in other board, society, committee or advocacy | | | | | |
| | group, paid or unpaid | | | | | |
| 11 | Stock or stock options | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 12 | Receipt of equipment, | X_None | | | | |
| | materials, drugs, medical | | | | | |
| | writing, gifts or other services | | | | | |
| 42 | | V N | | | | |
| 13 | Other financial or non- financial interests | XNone | | | | |
| | inialiciai inicerests | | | | | |
| | | | | | | |
| | | | | | | |
| Please summarize the above conflict of interest in the following box: | | | | | | |
| | | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |

| Date: 7 th October, 2022 |
|--|
| Your Name: Orsolya Gobel |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in reducing symptoms of post |
| COVID syndrome |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | • | XNone | | | | |
|---|--|---------|--|--|--|--|
| | lectures, presentations, speakers bureaus, | | | | | |
| | manuscript writing or | | | | | |
| | educational events | | | | | |
| 6 | Payment for expert | XNone | | | | |
| | testimony | | | | | |
| _ | Command for adding | V. Nama | | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 8 | Patents planned, issued or | XNone | | | | |
| | pending | | | | | |
| | | | | | | |
| 9 | Participation on a Data | XNone | | | | |
| | Safety Monitoring Board or | | | | | |
| | Advisory Board | | | | | |
| 10 | Leadership or fiduciary role | XNone | | | | |
| | in other board, society, committee or advocacy | | | | | |
| | group, paid or unpaid | | | | | |
| 11 | Stock or stock options | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 12 | Receipt of equipment, | X_None | | | | |
| | materials, drugs, medical | | | | | |
| | writing, gifts or other services | | | | | |
| 42 | | V N | | | | |
| 13 | Other financial or non- financial interests | XNone | | | | |
| | inialiciai inicerests | | | | | |
| | | | | | | |
| | | | | | | |
| Please summarize the above conflict of interest in the following box: | | | | | | |
| | | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |

| Date: 7 th October, 2022 |
|---|
| Your Name: Orsolya Kovács |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in reducing symptoms of post- |
| COVID syndrome |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initia | l planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X_None | |
| 4 | Consulting fees | XNone | |

| 5 | · · · · · · · · · · · · · · · · · · · | XNone | | | | |
|------|---|---------|--|--|--|--|
| | lectures, presentations, speakers bureaus, | | | | | |
| | manuscript writing or | | | | | |
| | educational events | | | | | |
| 6 | Payment for expert | XNone | | | | |
| | testimony | | | | | |
| _ | Command for adding | V. Nama | | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 8 | Patents planned, issued or | XNone | | | | |
| | pending | | | | | |
| | | | | | | |
| 9 | Participation on a Data | XNone | | | | |
| | Safety Monitoring Board or | | | | | |
| | Advisory Board | | | | | |
| 10 | Leadership or fiduciary role | XNone | | | | |
| | in other board, society, committee or advocacy | | | | | |
| | group, paid or unpaid | | | | | |
| 11 | Stock or stock options | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 12 | Receipt of equipment, | X_None | | | | |
| | materials, drugs, medical | | | | | |
| | writing, gifts or other services | | | | | |
| 42 | | V N | | | | |
| 13 | Other financial or non- financial interests | XNone | | | | |
| | inialiciai inicerests | | | | | |
| | | | | | | |
| | | | | | | |
| Plea | Please summarize the above conflict of interest in the following box: | | | | | |
| | | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |

| Date: 7 th October, 2022 |
|---|
| Your Name: Kata Gyongyosi |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in reducing symptoms of pos |
| COVID syndrome |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | · · · · · · · · · · · · · · · · · · · | XNone | | | | |
|------|---|---------|--|--|--|--|
| | lectures, presentations, speakers bureaus, | | | | | |
| | manuscript writing or | | | | | |
| | educational events | | | | | |
| 6 | Payment for expert | XNone | | | | |
| | testimony | | | | | |
| _ | Command for adding | V. Nama | | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 8 | Patents planned, issued or | XNone | | | | |
| | pending | | | | | |
| | | | | | | |
| 9 | Participation on a Data | XNone | | | | |
| | Safety Monitoring Board or | | | | | |
| | Advisory Board | | | | | |
| 10 | Leadership or fiduciary role | XNone | | | | |
| | in other board, society, committee or advocacy | | | | | |
| | group, paid or unpaid | | | | | |
| 11 | Stock or stock options | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 12 | Receipt of equipment, | X_None | | | | |
| | materials, drugs, medical | | | | | |
| | writing, gifts or other services | | | | | |
| 42 | | V N | | | | |
| 13 | Other financial or non- financial interests | XNone | | | | |
| | inialiciai inicerests | | | | | |
| | | | | | | |
| | | | | | | |
| Plea | Please summarize the above conflict of interest in the following box: | | | | | |
| | | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |

| Date: 7 th October, 2022 |
|--|
| Your Name: Renata Pinter |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in reducing symptoms of post |
| COVID syndrome |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initia | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | · · · · · · · · · · · · · · · · · · · | X_None | | | | |
|------|---|---------|--|--|--|--|
| | lectures, presentations, speakers bureaus, | | | | | |
| | manuscript writing or | | | | | |
| | educational events | | | | | |
| 6 | Payment for expert | XNone | | | | |
| | testimony | | | | | |
| _ | Command for adding | V. Nama | | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 8 | Patents planned, issued or | XNone | | | | |
| | pending | | | | | |
| | | | | | | |
| 9 | Participation on a Data | XNone | | | | |
| | Safety Monitoring Board or | | | | | |
| | Advisory Board | | | | | |
| 10 | Leadership or fiduciary role | XNone | | | | |
| | in other board, society, committee or advocacy | | | | | |
| | group, paid or unpaid | | | | | |
| 11 | Stock or stock options | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 12 | Receipt of equipment, | X_None | | | | |
| | materials, drugs, medical | | | | | |
| | writing, gifts or other services | | | | | |
| 42 | | V N | | | | |
| 13 | Other financial or non- financial interests | XNone | | | | |
| | inialiciai inicerests | | | | | |
| | | | | | | |
| | | | | | | |
| Plea | Please summarize the above conflict of interest in the following box: | | | | | |
| | | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |

| Date: 7" October, 2022 |
|--|
| Your Name: Zsuzsanna Kovats |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in reducing symptoms of post |
| COVID syndrome |
| Manuscript number (if known): |
| |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initia | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X_None | |
| 4 | Consulting fees | XNone | |

| 5 | • | X_None | | | | |
|---|--|---------|--|--|--|--|
| | lectures, presentations, speakers bureaus, | | | | | |
| | manuscript writing or | | | | | |
| | educational events | | | | | |
| 6 | Payment for expert | XNone | | | | |
| | testimony | | | | | |
| _ | Command for adding | V. Nama | | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 8 | Patents planned, issued or | XNone | | | | |
| | pending | | | | | |
| | | | | | | |
| 9 | Participation on a Data | XNone | | | | |
| | Safety Monitoring Board or | | | | | |
| | Advisory Board | | | | | |
| 10 | Leadership or fiduciary role | XNone | | | | |
| | in other board, society, committee or advocacy | | | | | |
| | group, paid or unpaid | | | | | |
| 11 | Stock or stock options | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 12 | Receipt of equipment, | X_None | | | | |
| | materials, drugs, medical | | | | | |
| | writing, gifts or other services | | | | | |
| 42 | | V N | | | | |
| 13 | Other financial or non- financial interests | XNone | | | | |
| | inialiciai inicerests | | | | | |
| | | | | | | |
| | | | | | | |
| Please summarize the above conflict of interest in the following box: | | | | | | |
| | | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |

| Date: 7 th October, 2022 |
|--|
| Your Name: Zoltan Ungvari |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in reducing symptoms of post |
| COVID syndrome |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initia | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X_None | |
| 4 | Consulting fees | XNone | |

| 5 | • | X_None | | | | |
|---|--|---------|--|--|--|--|
| | lectures, presentations, speakers bureaus, | | | | | |
| | manuscript writing or | | | | | |
| | educational events | | | | | |
| 6 | Payment for expert | XNone | | | | |
| | testimony | | | | | |
| _ | Command for adding | V. Nama | | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 8 | Patents planned, issued or | XNone | | | | |
| | pending | | | | | |
| | | | | | | |
| 9 | Participation on a Data | XNone | | | | |
| | Safety Monitoring Board or | | | | | |
| | Advisory Board | | | | | |
| 10 | Leadership or fiduciary role | XNone | | | | |
| | in other board, society, committee or advocacy | | | | | |
| | group, paid or unpaid | | | | | |
| 11 | Stock or stock options | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 12 | Receipt of equipment, | X_None | | | | |
| | materials, drugs, medical | | | | | |
| | writing, gifts or other services | | | | | |
| 42 | | V N | | | | |
| 13 | Other financial or non- financial interests | XNone | | | | |
| | inialiciai inicerests | | | | | |
| | | | | | | |
| | | | | | | |
| Please summarize the above conflict of interest in the following box: | | | | | | |
| | | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |

| Date: 7 th October, 2022 |
|---|
| Your Name: Stefano Tarantini |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in reducing symptoms of pos |
| COVID syndrome |
| Manuscript number (if known): |
| |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initia | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X_None | |
| 4 | Consulting fees | XNone | |

| 5 | • | X_None | | | | |
|---|--|---------|--|--|--|--|
| | lectures, presentations, speakers bureaus, | | | | | |
| | manuscript writing or | | | | | |
| | educational events | | | | | |
| 6 | Payment for expert | XNone | | | | |
| | testimony | | | | | |
| _ | Command for adding | V. Nama | | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 8 | Patents planned, issued or | XNone | | | | |
| | pending | | | | | |
| | | | | | | |
| 9 | Participation on a Data | XNone | | | | |
| | Safety Monitoring Board or | | | | | |
| | Advisory Board | | | | | |
| 10 | Leadership or fiduciary role | XNone | | | | |
| | in other board, society, committee or advocacy | | | | | |
| | group, paid or unpaid | | | | | |
| 11 | Stock or stock options | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 12 | Receipt of equipment, | X_None | | | | |
| | materials, drugs, medical | | | | | |
| | writing, gifts or other services | | | | | |
| 42 | | V N | | | | |
| 13 | Other financial or non- financial interests | XNone | | | | |
| | inialiciai inicerests | | | | | |
| | | | | | | |
| | | | | | | |
| Please summarize the above conflict of interest in the following box: | | | | | | |
| | | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |

| Date: 7 th October, 2022 |
|--|
| Your Name: Gabor Horvath |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in reducing symptoms of post |
| COVID syndrome |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initia | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X_None | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | X_None | | | | |
|------|--|---------------------------------|------------|--|--|--|
| | lectures, presentations, speakers bureaus, | | | | | |
| | manuscript writing or | | | | | |
| | educational events | | | | | |
| 6 | Payment for expert | XNone | | | | |
| | testimony | | | | | |
| _ | Company for attack disc. | V. Nama | | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 8 | Patents planned, issued or | XNone | | | | |
| | pending | | | | | |
| | | | | | | |
| 9 | Participation on a Data | XNone | | | | |
| | Safety Monitoring Board or | | | | | |
| | Advisory Board | | | | | |
| 10 | Leadership or fiduciary role | XNone | | | | |
| | in other board, society, committee or advocacy | | | | | |
| | group, paid or unpaid | | | | | |
| 11 | Stock or stock options | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 12 | Receipt of equipment, | X_None | | | | |
| | materials, drugs, medical | | | | | |
| | writing, gifts or other services | | | | | |
| 13 | Other financial or non- | X None | | | | |
| 13 | financial interests | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| Plea | ase summarize the above co | nflict of interest in the follo | owing box: | | | |
| | | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |

| Date: 7 th October, 2022 | |
|---|-------------------------------------|
| Your Name: Veronika Muller | |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation pro | ogramme in reducing symptoms of pos |
| COVID syndrome | |
| Manuscript number (if known): | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initia | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | X_None | | | | |
|------|--|---------------------------------|------------|--|--|--|
| | lectures, presentations, speakers bureaus, | | | | | |
| | manuscript writing or | | | | | |
| | educational events | | | | | |
| 6 | Payment for expert | XNone | | | | |
| | testimony | | | | | |
| _ | Company for attack disc. | V. Nama | | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 8 | Patents planned, issued or | XNone | | | | |
| | pending | | | | | |
| | | | | | | |
| 9 | Participation on a Data | XNone | | | | |
| | Safety Monitoring Board or | | | | | |
| | Advisory Board | | | | | |
| 10 | Leadership or fiduciary role | XNone | | | | |
| | in other board, society, committee or advocacy | | | | | |
| | group, paid or unpaid | | | | | |
| 11 | Stock or stock options | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 12 | Receipt of equipment, | X_None | | | | |
| | materials, drugs, medical | | | | | |
| | writing, gifts or other services | | | | | |
| 13 | Other financial or non- | X None | | | | |
| 13 | financial interests | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| Plea | ase summarize the above co | nflict of interest in the follo | owing box: | | | |
| | | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |

| Date: / "October, 2022 |
|---|
| Your Name: Janos Tamas Varga |
| Manuscript Title: Effectiveness of complex cardiopulmonary rehabilitation programme in reducing symptoms of post- |
| COVID syndrome |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | X_None | | | | |
|------|--|---------------------------------|------------|--|--|--|
| | lectures, presentations, speakers bureaus, | | | | | |
| | manuscript writing or | | | | | |
| | educational events | | | | | |
| 6 | Payment for expert | XNone | | | | |
| | testimony | | | | | |
| _ | Company for attack disc. | V. Nama | | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 8 | Patents planned, issued or | XNone | | | | |
| | pending | | | | | |
| | | | | | | |
| 9 | Participation on a Data | XNone | | | | |
| | Safety Monitoring Board or | | | | | |
| | Advisory Board | | | | | |
| 10 | Leadership or fiduciary role | XNone | | | | |
| | in other board, society, committee or advocacy | | | | | |
| | group, paid or unpaid | | | | | |
| 11 | Stock or stock options | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 12 | Receipt of equipment, | X_None | | | | |
| | materials, drugs, medical | | | | | |
| | writing, gifts or other services | | | | | |
| 13 | Other financial or non- | X None | | | | |
| 13 | financial interests | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| Plea | ase summarize the above co | nflict of interest in the follo | owing box: | | | |
| | | | | | | |

| None. | | | |
|-------|--|--|--|
| | | | |